Avalanche Biotechnologies Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Avalanche Posts Wider-than-Expected 4Q Loss
Article By: Zacks Investment Research
Thursday, March 3, 2016 11:04 AM EDT
Being a development-stage company, Avalanche does not have any approved product in its portfolio yet. In this scenario, investors are expected to keep an eye on pipeline development at the company, apart from the usual bottom-line numbers.
In this article: AAVL
Read
Uncertainty Weighs Down On The Market - Markets This Morning
Article By: Amigobulls
Wednesday, September 30, 2015 2:52 PM EDT
The factors that set this bear market in motion – cuts in margin debt, low commodity prices, Chinese uncertainty – remain in place.
In this article: PBR, STO, VRX, XOM, LNG, GLNCY, VLKAY, IBB, AAPL, AMZN, COMP, FB, SPX, DJI, QURE, AAVL, ONCE
Read
E Avalanche Announces Phase 2 Wet AMD Trial Headed Back To The Lab
Article By: Terry Chrisomalis
Friday, August 14, 2015 8:34 PM EDT
Shares of Avalanche tumbled today 27% after the company reported that it won't advance its phase 2 AVA-101 Wet AMD gene therapy treatment for the time being
In this article: AAVL
Read
Tuesday Morning Pre-Market Insights: AERI, NOK, AAVL, TNXP
Article By: TipRanks
Tuesday, June 16, 2015 8:36 AM EDT
Tuesday Morning Pre-Market Insights: AERI, NOK, AAVL, TNXP
In this article: AAVL, AERI, NOK, TNXP
Read
E Shares Of Avalanche Biotech Plummet After-Hours After Mediocre Results In Macular Degeneration Study
Article By: Terry Chrisomalis
Monday, June 15, 2015 7:28 PM EDT
Shares of Avalanche Biotech are down 40% in after-hours trade today after reporting mediocre phase 2 results in Macular Degeneration. The stock dropped 6% during market hours.
In this article: AAVL, REGN, RHHBY
Read

PARTNER HEADLINES

Latest Tweets for $AAVL

No tweets yet!